From 2023 to 2024, around *** percent of college and university students who received mental health services had received treatment for drug and alcohol use. This statistic shows the percentage of college and university students in the U.S. who received mental health services and received treatment for alcohol or drug use from 2010 to 2024.

The Alcohol and Other Drug Treatment Services (AODTS) National Minimum Data Set (NMDS) is an annual collection of information regarding the clients who use alcohol and other drug treatment services, the types of drug problems for which treatment is sought and the types of treatment they receive.

From 2015-2021.

The California Drug and Alcohol Treatment Assessment
(CALDATA) was designed to study the costs, benefits, and effectiveness
of the state's alcohol and drug treatment infrastructure (recovery
services) and specifically to assess (1) the effects of treatment on
participant behavior, (2) the costs of treatment, and (3) the economic
value of treatment to society. Data were collected on participants
(clients) across four types of treatment programs, or modalities:
residential, residential "social model," nonmethadone outpatient, and
outpatient methadone (detoxification and maintenance). Data were
collected in two phases. In Phase 1, treatment records were abstracted
for clients who received treatment or were discharged between October
1, 1991, and September 30, 1992. In Phase 2, these clients were
located and recruited for a follow-up interview. The CALDATA design
and procedures included elements from several national treatment
outcome studies including the Drug Services Research Survey, Services Research Outcomes Study, National
Treatment Improvement Evaluation Study, and Drug Abuse
Treatment Outcome Study. The record abstract was designed
to collect identifying and locating information for interview
reference during the personal interviewing phase. The abstract also
collected demographic, drug, or alcohol use, and treatment and service
information. The follow-up questionnaire covered time periods before,
during, and after treatment and focused on topics such as ethnic and
educational background, drug and alcohol use, mental and physical
health, HIV and AIDS status, drug testing, illegal activities and
criminal status, living arrangements and family issues, employment and
income, and treatment for drug, alcohol, and mental health
problems. Drugs included alcohol, barbiturates, benzodiazepines,
cocaine powder, crack, downers, hallucinogens, heroin, illegal
methadone, inhalants, LSD, marijuana/hashish/THC, methamphetamines and
other stimulants, narcotics, over-the-counter drugs, PCP, ritalin or
preludin, and sedatives/hypnotics. CALDATA was originally known as the
California Outcomes Study (COS).This study has 1 Data Set.

Drug Abuse Treatment Outcome Study - Adolescent (DATOS-A) was a multisite, prospective, community-based, longitudinal study of adolescents entering treatment. It was designed to evaluate the effectiveness of adolescent drug treatment by investigating the characteristics of the adolescent population, the structure and process of drug abuse treatment in adolescent programs, and the relationship of these factors with outcomes. Three major types or modalities of programs included in the study were chemical dependency or short-term inpatient (STI), therapeutic community or residential (RES), and outpatient drug-free (ODF). The adolescent battery of instruments included intake, intreatment, and follow-up questionnaires based largely on the DATOS adult study DRUG ABUSE TREATMENT OUTCOME STUDY (DATOS), 1991-1994: UNITED STATES instrument format, with considerable tailoring to the adolescent population. Clients entering treatment completed two comprehensive intake interviews (Intake 1 and Intake 2), approximately one week apart. This information is provided in Parts 1 and 2 of the data collection. These interviews were designed to obtain baseline data on drug use and other behaviors, such as illegal involvement, as well as information on background and demographic characteristics, education and training, mental health status, employment, income and expenditures, drug and alcohol dependence, health, religiosity and self-concept, and motivation and readiness for treatment. The one-, three-, and six-month intreatment interviews (Parts 3, 4, and 7) included items on treatment access, intreatment experience, and psychological functioning, as well as questions replicated from some of the domains in the Intake 1 and 2 questionnaires. The 12-month post-treatment follow-up interview (Part 5) included questions replicated from the previous interviews, and also included post-treatment status. Part 6 includes variables for time in treatment and interview availability indicators. The Measures Data (Part 8) were generated by using the Diagnostic and Statistical Manual of Mental Disorders (Rev. 3rd ed., DSM-III-R) (American Psychiatric Association, 1987). The variables in Part 8 give either the DSM-III-R level of dependence to a drug category or they describe whether the subject meets the DSM-III-R standard for a particular disorder. The 12-Month Follow-up Urine Result data (Part 9) provide the results from urine sample tests that were given to a sample of subjects at the time of the 12-Month Follow-up Interview. The urine test was used to ascertain the nature and extent of bias in the self-reports of the respondents. Urine specimens were tested for eight categories of drugs (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolite, methaqualone, opiates, and phencyclidine). The drugs covered in the study were alcohol, tobacco, marijuana (hashish, THC), cocaine (including crack), heroin, narcotics or opiates such as morphine, codeine, Demerol, Dilaudid, and Talwin, illegal methadone, sedatives and tranquilizers such as barbiturates and depressants, amphetamines or other stimulants such as speed or diet pills, methamphetamines, LSD, PCP, and other hallucinogens or psychedelics, and inhalants such as glue, gasoline, paint thinner, and aerosol sprays. The study also included drug of choice, frequency, and route of administration.

Database of the nation''s substance abuse and mental health research data providing public use data files, file documentation, and access to restricted-use data files to support a better understanding of this critical area of public health. The goal is to increase the use of the data to most accurately understand and assess substance abuse and mental health problems and the impact of related treatment systems. The data include the U.S. general and special populations, annual series, and designs that produce nationally representative estimates. Some of the data acquired and archived have never before been publicly distributed. Each collection includes survey instruments (when provided), a bibliography of related literature, and related Web site links. All data may be downloaded free of charge in SPSS, SAS, STATA, and ASCII formats and most studies are available for use with the online data analysis system. This system allows users to conduct analyses ranging from cross-tabulation to regression without downloading data or relying on other software. Another feature, Quick Tables, provides the ability to select variables from drop down menus to produce cross-tabulations and graphs that may be customized and cut and pasted into documents. Documentation files, such as codebooks and questionnaires, can be downloaded and viewed online.

As of 2023, there were over *********** outpatient facilities in Italy providing services for the treatment, prevention, and rehabilitation of people with drug addiction. With **, Lombardy was the Italian region with the highest number of outpatient centers providing these services, followed by Piedmont and Apulia. This statistic displays the number of outpatient facilities offering different kinds of healthcare services to people with drug addiction in Italy in 2023, by region.

The Estonian Drug Treatment Database is a state register which is kept on the people who have started drug treatment. The Drug Treatment Database started its work on January 1, 2008.

Collection and processing of data on these people is necessary for getting an overview on occurrence of mental and behavioural disorders related to drug use, as well as for organising of relevant health services and planning of drug abuse preventive actions. Health care institutions holding a psychiatry authorization in Estonia present data to the database if they are turned to by a patient who is diagnosed with a mental and behavioural disorder due to drug use.

On the basis of the database's data, an annual overview is compiled, giving information about drug addicts who have turned to drug treatment in the previous calendar year, about the health service provided, the patients' socio-economic background, drug use and the related risk behaviour.

The data on the Drug Treatment Database are also submitted to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and United Nations Office on Drugs and Crime (UNODC).

In 2024, there were 17,829 substance use treatment facilities in the country, an increase from the year before. Moreover, there were also over 9,000 facilities that provided both mental health and substance abuse treatment.

The PA Drug Alcohol Treatment Facilities dataset includes facilities that specialize in the evaluation and treatment of drug addiction, alcoholism and associated disorders. When possible, efforts were made to confirm the rooftop location of each drug and alcohol treatment facility. The accuracy of geocoding is available in Geocoding Certainty attribute field (Geocoding Certainty: Rooftop="00", Street="01", Zip Centroid="04", Not geocoded="99").

This is an alphabetical list by county of all non-medical alcoholism and drug abuse recovery or treatment facilities licensed and/or certified by the Department of Health Care Services (DHCS). Within DHCS, the Substance Use Disorder Compliance (SUDC) Division Licensing and Certification Branch (LCB) is responsible for assuring that quality services are provided to all program participants in a safe and healthful environment through the licensure, certification, regulation, and oversight of a statewide system of alcohol and other drug recovery and treatment facilities and programs and counselors.

Addictive disorders are chronic conditions for many women. Substance use during pregnancy is especially worrisome. Moreover, major depressive disorder often co-occurs with substance abuse among women. Therefore, pregnant women with substance abuse are complex patients. Priority populations (e.g., minority group members) are greatly over-represented among pregnant substance abusers. Treatment can be effective for female substance abusers but few (if any) data are available regarding comparative effectiveness of residential versus outpatient treatment for pregnant women with addictions. Residential treatment, by definition, provides shelter and reduces availability of substances in addition to delivering care for chemical dependency. However, residential treatment removes patients from their usual home and work environments and is more expensive than outpatient care. Although not focusing on pregnant substance abusers, studies have generally found little difference in outcomes for residential versus outpatient chemical dependency treatment. On the other hand, research has also suggested patient factors may moderate treatment impact so that sub-groups of substance abusers differentially benefit from residential (versus outpatient) care. To address these issues, this analytic epidemiologic study addresses "the benefits and harms of preventive or therapeutic interventions in 'real world' settings for patients who have multiple chronic co-morbid conditions." The chief focus is pregnant women (many of whom also have major depressive disorder) obtaining treatment for chemical dependency. The intervention is specialty sector substance abuse treatment. The "real world" settings are publicly financed substance abuse treatment programs. Among several data sets, the project employs newly available information from the nation-wide Treatment Episode Data Set (TEDS) discharge database. The project utilizes innovative statistical techniques (including non-linear instrumental variables approaches) to examine the comparative effectiveness of outpatient versus residential substance abuse treatment.​

The National Drug Abuse Treatment System Survey (NDATSS) is a longitudinal program of research into organizational structures, operating characteristics, and treatment modalities of outpatient drug treatment programs in the United States. This is done through interviews with program directors and clinical supervisors. In some publications, this research is referred to as the Outpatient Drug Abuse Treatment Studies (ODATS). Data being released include Wave II (1988), Wave III (1990), and Wave IV (1995).

In financial year 2021, over *** thousand people in India received drug de-addiction treatment. It was significantly higher compared to the previous financial year. However, this was still a decrease from the number of people under de-addiction treatment in financial year 2016.

Abstract Background In Portugal, as far as we know, there are no recent studies that evaluated the comparative efficacy of therapeutic modalities in addiction problems by reference to a holistic and psychosocial model of effectiveness. Objectives Using a sample of Portuguese patients in outpatient treatment for drug and alcohol abuse, this study aimed to examine if a combined treatment modality (group therapy with individual intervention) had greater overall efficacy when compared to other three types of treatment without group therapy. Methods This is a correlational and cross-sectional study using a convenience sample of patients (N = 254) from an outpatient treatment in the Intervention Service on Addictive Behaviors and Substance Dependence. At the time of data collection, the patients were attending four types of treatment, such as receiving intervention based on individual psychological counseling (n = 66); receiving individual psychiatric counseling (n = 68); receiving both individual psychological and psychiatric counseling (n = 102); and receiving not only individual counseling (i.e., psychology or psychiatry), but also attending group therapy (n = 18). Results Using MANOVA and Wilks’s multivariate test criterion, there was a significant effect of treatment modality on the global efficacy, Λ = 0.88, F(9, 603) = 3.75, p < 0.0001. Examination of mean estimates indicated that patients in a combined therapeutic modality revealed more treatment involvement compared to patients in other therapeutic modalities without group therapy. Discussion The results obtained in this study highlight the importance of integrating interventions in a collaborative way. A combined therapeutic modality, adding group therapy, was associated with positive effects, such as more levels of peer support and involvement in treatment, and increasing the individual’s probability to remain abstinent.

In 2022, the highest number of people admitted for treatment because of substance abuse consumed cannabis, followed by opium-based substances. At the same time, *** people were treated for cocaine consumption.

According to a survey on substance use in India between ************* and ************, it was found that amongst the people who were seeking help for their substance addiction, only ** percent of alcoholics were hospitalized, while ** percent received other forms of treatment like spiritual or religious help, or help from a non-governmental organization. However, for drug addiction, around ** percent of dependents stated they received in-patient hospital treatment.

This report presents an evaluation of the coverage, overlap, biases, strengths, and weaknesses of three sources of data on the receipt of specialty substance use treatment: the National Survey on Drug Use and Health (NSDUH), the National Survey of Substance Abuse Treatment Services (N-SSATS), and the Treatment Episode Data Set (TEDS). Specialty substance use treatment measures compared include numbers and characteristics of persons treated in a given year, single-day treatment counts, numbers of admissions in a given year, and estimates of the numbers of persons who needed substance use treatment but did not receive it. This report includes data from the 2005 through 2010 NSDUHs; 2007 through 2009 N-SSATS; and 2007 through 2009 TEDS. Results are show by substance treated, age, race/ethnicity, and employment status,